The next 12 months will see OptiBiotix Health plc (LON:OPTI) make the transition from a technology company to a product company.
The company said in its results statement covering 2016 that this year will see the microbiome specialist build revenue streams from a diverse range of products.
This process started in August 2016 with the launch of the company’s GoFigure products based on its SlimBiome platform and will continue next month with the launch of its LPLDL cholesterol reducing strain.
SIGN UP to the Proactive Investors newsletter
READ the OptiBiotix investment case
WATCH OptiBiotix boss talk about the transition process
Later this year, the company expects to launch the first generation of SweetBiotix, its natural sweet fibre to help with diabetes control.
The company now has an intellectual portfolio covering 50 patents across 15 product families; eight strain registrations and 16 trademarks.
OptioBiotix has a broad portfolio of intellectual property platforms
“OptiBiotix now has a broad portfolio of IP, multiple technology platforms, and an increasing range of products entering the market, and believes it is well placed to build on this solid foundation to build a microbiome business with significant future value for shareholders,” the company said.
Meanwhile, looking in the rear view mirror, the company saw a sharp increase in revenue in the year to 30 November 2016 but from a very small base. Revenue rose to £288,119 from £28,200 the year before.
The loss before tax was more or less steady at £1.52mln, compared to £1.42mln the year before.